Comparative study of choline alfoscerate as a combination therapy with donepezil: A mixed double-blind randomized controlled and open-label observation trial
Lee W, Kim M
Published in Medicine (Baltimore)
Methodology
Mixed double-blind randomized controlled and open-label trial in 119 patients with cognitive decline (MMSE 26 or less) assigned to donepezil alone, donepezil plus choline alfoscerate, donepezil plus acetyl-L-carnitine, or donepezil plus ginkgo biloba, assessed at 12 and 24 weeks.
Key Findings
At 24 weeks the donepezil plus choline alfoscerate group improved ADAS-Cog by 18.5% versus 9.4% with donepezil alone, with better MMSE and noncognitive subscale performance than donepezil alone.
Conclusions
Choline alfoscerate added to donepezil produced additional cognitive and noncognitive improvement, supporting the ASCOMALVA findings.
Limitations
Mixed randomized/open-label design, modest sample split across four arms, percentage-change reporting without effect sizes, single-country setting.
Supplements Studied
Choline alfoscerate exhibits additional cognitive improvement in both cognitive and noncognitive domains, supporting the findings of the ASCOMALVA trial.
Outcomes Measured
At the 24th week, ADAS-Cog showed improvement in the DN group by 18.5%, whereas it improved by 9.4% in the DO group.
Study Details
Access Study
Disclosures
Funding
Academic (Chungnam and Seoul National University Hospitals)
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.